Search
Now showing items 1-4 of 4
The application of metabolomics toward pulmonary tuberculosis research
(Elsevier, 2019)
In the quest to identify novel biomarkers for pulmonary tuberculosis (TB), high-throughput systems biology approaches such as metabolomics has become increasingly widespread. Such biomarkers have not only successfully been ...
Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin
(Elsevier, 2020)
Isoniazid and rifampicin are well-known anti-mycobacterial agents and are widely used to treat pulmonary tuberculosis (TB) as part of the combined therapy approach, recommended by the World Health Organization. The ingestion ...
Metabolomics biomarkers for tuberculosis diagnostics: current status and future objectives
(Future Medicine, 2017)
Numerous studies have contributed to our current understanding of the complex biology of pulmonary tuberculosis and subsequently provided solutions to its control or eradication. Metabolomics, a newcomer to the Omics ...
The role of metabolomics in tuberculosis treatment research
(Future Medicine, 2017)
Despite the fact that tuberculosis (TB) is a curable disease, it still results in approximately 1.8 million deaths annually. Various inadequacies in the current TB treatment strategies are major contributors to this high ...